Who is sponsoring NCT05640336?

NCT05640336 is sponsored by Mayo Clinic.

What condition does NCT05640336 study?

NCT05640336 studies Periprosthetic Joint Infection.

What drugs are being tested in NCT05640336?

Interventions: Single Debridement, Antibiotics and Implant Retention, Planned Double Debridement, Antibiotics and Implant Retention.

What is the status of NCT05640336?

NCT05640336 is currently ENROLLING_BY_INVITATION.

Last reviewed 2025-12-10 · How we verify

Single vs Planned Double-Debridement Antibiotics and Implant Retention Followed by Chronic Antibiotic Suppression for the Treatment of Acute Periprosthetic Joint Infection: A Prospective, Multicenter, Randomized Clinical Trial

NCT05640336 NA ENROLLING_BY_INVITATION

The purpose of this research is to evaluate two different standard of care surgeries in treating periprosthetic joint infection (PJI) after total hip and knee arthroplasty. Researchers are looking at differences in outcomes following single versus planned double debridement, antibiotics, and implant retention (DAIR) for acutely infected total hip arthroplasty (THA), and total knee arthroplasties (TKAs).

Details

Lead sponsor	Mayo Clinic
Phase	NA
Status	ENROLLING_BY_INVITATION
Enrolment	490
Start date	2023-03-03
Completion	2032-03

Conditions

Periprosthetic Joint Infection

Interventions

Single Debridement, Antibiotics and Implant Retention
Planned Double Debridement, Antibiotics and Implant Retention

Primary outcomes

Subjects free from failure — 1 year following DAIR.
Total number of subjects considered failure free at one year from surgical DAIR procedure. Failure is defined as reoperation for infection within one year from surgical procedure.

Countries

United States